Literature DB >> 191529

Specificities of killing by cytotoxic lymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells.

L R Gooding.   

Abstract

Cell-mediated immunity to SV40-transformed C3H and C3H-SW cell lines was measured by using both 51Cr and 125IUdR release assays. Killing by cytotoxic cells generated on in vitro sensitization of immune spleen cells with syngeneic SV40 cells by either assay is specific for syngeneic SV40 transformants. Cytolysis mediated by in vitro sensitized cells is ablated by treatment of the effector cells with anti-theta serum and complement. Intraperitoneal immunization with syngeneic SV40 cells yields two distinct killer-cell populations in the peritoneal exudate when assayed by 125IUdR release. The first, nylon wool nonadherent and sensitive to anti-theta and complement, is indistinguishable from the killers generated in vitro. The second population, present in larger numbers and more efficient on a per-cell basis in killing of SV40 targets than the first, is nylon adherent and is not removed by treatment with anti-theta and complement. This second population will kill any SV40 transformed target, whether syngeneic or allogeneic. The possible roles of T cell and non-T cell effectors in rejection of syngeneic SV40 tumors are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 191529

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Molecular mapping within the mouse albino-deletion complex.

Authors:  D K Johnson; R E Hand; E M Rinchik
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

2.  Idiotype network components are involved in the murine immune response to simian virus 40 large tumor antigen.

Authors:  R L Mernaugh; M H Shearer; R K Bright; R E Lanford; R C Kennedy
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Generation of cytotoxic T lymphocytes against immunorecessive epitopes after multiple immunizations with adenovirus vectors is dependent on haplotype.

Authors:  T E Sparer; S G Wynn; D J Clark; J M Kaplan; L M Cardoza; S C Wadsworth; A E Smith; L R Gooding
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Macrophage-resistant murine simian virus 40 tumors express a retroviral type-specific gp70.

Authors:  S K Chapes; A E O'Neill; L Flaherty; L R Gooding
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

5.  Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo.

Authors:  S C Wadsworth; H Zhou; A E Smith; J M Kaplan
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  SV40 T antigen acts as a minor histocompatibility antigen of SV40 T antigen tolerant transgenic mice.

Authors:  A Juretic; B B Knowles
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

7.  Comparison of the murine humoral immune response to recombinant simian virus 40 large tumor antigen: epitope specificity and idiotype expression.

Authors:  R K Bright; M H Shearer; R C Kennedy
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

8.  Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.

Authors:  O Utermöhlen; C Schulze-Garg; G Warnecke; R Gugel; J Löhler; W Deppert
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model.

Authors:  T E Sparer; R A Tripp; D L Dillehay; T W Hermiston; W S Wold; L R Gooding
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Simian virus 40 T-antigen-related cell surface antigen: serological demonstration on simian virus 40-transformed monolayer cells in situ.

Authors:  W Deppert; K Hanke; R Henning
Journal:  J Virol       Date:  1980-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.